CareDx says final Medicare LCD maintains coverage for transplant rejection surveillance tests
PUBT · 20h ago
Share
Listen to the news
- CareDx clarified that Medicare finalized a Local Coverage Determination supporting molecular surveillance testing for solid organ transplant rejection.
- Policy maintains coverage across kidney, heart, lung offerings, setting surveillance test frequency limits for years 1-3 post-transplant; for-cause testing unchanged.
- Final LCD published July 16, 2026; effective Aug. 30, 2026, reducing reimbursement uncertainty for key transplant testing products.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260716462755) on July 16, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved